In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Amanda Fader to discuss the role of trastuzumab in uterine papillary serous tumors. Dr. Fader is an Associate Professor of Gynecology and Obstetrics, Vice Chair of Gynecologic Surgical Operations and Director of the Center for Rare Gynecologic Cancers at Johns Hopkins School of Medicine. She is recognized internationally as a rare uterine and ovarian cancer expert and is an active member of NRG Oncology and...
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Amanda Fader to discuss the role of trastuzumab in uterine papillary serous tumors. Dr. Fader is an Associate Professor of Gynecology and Obstetrics, Vice Chair of Gynecologic Surgical Operations and Director of the Center for Rare Gynecologic Cancers at Johns Hopkins School of Medicine. She is recognized internationally as a rare uterine and ovarian cancer expert and is an active member of NRG Oncology and helps develop and co-lead innovative gynecologic cancer clinical trials.
Highlights:
• Uterine serous carcinoma (USC) is a biologically aggressive endometrial cancer subtype that accounts for a disproportionately high rate of endometrial cancer-related deaths.
• 25-30% of women with both early and advanced stage USC will have HER2 positive tumors.
• Molecularly-based therapeutic approaches in USC are increasing.
• Trastuzumab, an anti-HER2 therapy, in combination with platinum/taxane-based chemotherapy improves survival outcomes for women with HER2 positive USC.
• A randomized, Phase III cooperative group study is planned to study additional anti-HER2 therapies in women with all stages of USC.
